<DOC>
	<DOCNO>NCT00389441</DOCNO>
	<brief_summary>The primary purpose determine effective AG-013736 shrink thyroid cancer resistant radioactive iodine</brief_summary>
	<brief_title>Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer</brief_title>
	<detailed_description>Additional study detail : ass safety efficacy</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Radioiodinerefractory metastatic unresectable locallyadvanced thyroid cancer At least 1 measurable target lesion , define RECIST Thyroid lymphoma Previous treatment antiangiogenesis agents No myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , deep vein thrombosis pulmonary embolism within 12 month prior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>anti-angiogenic</keyword>
	<keyword>carcinoma</keyword>
	<keyword>papillary</keyword>
	<keyword>follicular</keyword>
	<keyword>medullary</keyword>
	<keyword>anaplastic</keyword>
</DOC>